Summary

The global pain management devices market is projected to reach USD 5,835.8 million by 2029 from USD 3,768.6 million in 2024, at a CAGR of 9.1% during the forecast period. The rapid growth in the geriatric population globally and the significant rise in the patients with chronic pain conditions are expected to boost the demand for pain management devices market. Moreover, gradual rise in utilization of pain management devices due to improved awareness among patients is likely to support the market growth. Advancements in pain management devices technology, new product launches, favourable reimbursement and government policies, investments in healthcare infrastructure, and initiatives to enhance the accessibility and affordability of pain management devices is anticipated to fuel the market growth.

“The Neurostimulation devices segment of pain management devices market to grow with the highest CAGR during the forecast period.”

Based on the pain management devices market, the Neurostimulation devices pain management devices segment is anticipated to grow at significant rate during forecast period. The demand for neurostimulation devices in the pain management market is increasing due to their effectiveness in treating chronic pain, their minimally invasive nature, and advancements in technology that enhance their functionality and patient comfort .These factors are fostering the growth of neurostimulation devices at higher pace.



“The neuropathic pain segment of application segment to capture the largest market share of pain management devices market.”
Based on application, the pain management devices market is segmented into neuropathic pain, musculoskeletal pain, cancer pain, facial & migraine , and other applications. The neuropathic segment is to capture the largest share and the higher CAGR during the forecast period. Owing to high prevalence of neuropathic pain across the globe, presence of substantial clinical evidence in the favor of high efficacy of pain management devices in neuropathic pain treatment, development of novel devices, the rising geriatric population is at high risk of neuropathic pain due to the increased incidence of neuropathic pain associated with many age-related diseases, side effects of drugs used to treat neuropathic pain, and availability of favorable reimbursement are boosting the adoption of pain management devices for neuropathic pain conditions.



“North America accounted for the largest share of the pain management devices market by region.”
The global pain management devices market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for pain management devices, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.
The largest share of North America is attributed to the high disease burden of chronic disease and pain conditions contributing to a larger pool of patients requiring pain management devices products. The presence of numerous potential market giants and favorable reimbursement policy in the region is likely to promote the growth of pain management devices market in North America.


A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–60%, Tier 2–30%, and Tier 3– 10%
• By Designation: Directors–50%, Managers–30% and Others–20%
• By Region: North America–45%, Europe–15%, Asia Pacific–25% and RoW–15%

The major players operating in the pain management devices market market are Medtronic (Ireland), Boston Scientific Corporation(US), Abbott Laboratories (US), Stryker (US), Nevro Corp. (US), Becton, Dickinson and Company (US), Baxter (US), B. Braun SE (Germany), Omron Corporation (Japan), Avanos Medical, Inc. (US), Teleflex Incorporated (US),ICU Medical, Inc. (US), Nipro (Japan), Moog Inc. (US), Atricure, Inc. (US), Micrel Medical Devices SA (Greece), Zynex, Inc.(US), and Enovis Corporation (US).
Research Coverage

This report studies the pain management devices market based on type, application, mode of purchase, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Analysis of Key divers (increasing prevalence of chronic pain conditions, rising demand of pain management devices in home care settings, , new product launches & approvals, favourable reimbursement scenario and government initiatives), restraints (high procedural cost, product recalls), Opportunities (emerging markets, expanding base of pain management clinics/centers ) , Challenge (stringent regulatory requirement, use of pain medication as first-line treatment for pain management)
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pain management devices market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the pain management devices market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pain management devices market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS AND EXCLUSIONS 28
1.3 STUDY SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED 30
1.3.3 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 31
1.5 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
2.1.1 SECONDARY DATA 33
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 35
2.1.2.1 Key data from primary sources 35
2.1.2.2 Insights from industry experts 36
2.1.2.3 Breakdown of primary interviews 36
2.1.2.4 Supply-side and demand-side participants 37
2.2 MARKET SIZE ESTIMATION 37
2.2.1 BOTTOM-UP APPROACH 37
2.2.2 TOP-DOWN APPROACH 40
2.3 DATA TRIANGULATION 41
2.4 RESEARCH ASSUMPTIONS 42
2.5 RESEARCH LIMITATIONS 42
2.6 RISK ASSESSMENT 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 48
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PAIN MANAGEMENT DEVICES MARKET 48
4.2 ASIA PACIFIC PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION AND COUNTRY 49
4.3 PAIN MANAGEMENT DEVICES MARKET, BY COUNTRY 50
 
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Surge in demand for at-home pain management devices 52
5.2.1.2 Increase in surgical procedures 52
5.2.1.3 Prevalence of chronic pain conditions 53
5.2.1.4 Favorable reimbursement policies for spinal cord stimulation devices 53
5.2.1.5 Growing launches and regulatory approvals for advanced
pain management devices 54
5.2.2 RESTRAINTS 54
5.2.2.1 Rise in product recalls 54
5.2.2.2 High procedural and purchase cost of pain management devices 55
5.2.3 OPPORTUNITIES 55
5.2.3.1 Untapped growth potential in emerging economies 55
5.2.3.2 Expansion of pain management clinics 56
5.2.4 CHALLENGES 56
5.2.4.1 Use of pain medication as first line of treatment 56
5.2.4.2 Stringent regulatory norms for FDA approval 56
5.3 TECHNOLOGY ANALYSIS 57
5.3.1 KEY TECHNOLOGIES 57
5.3.1.1 Wearable devices 57
5.3.1.2 Implantable pumps 57
5.3.2 COMPLEMENTARY TECHNOLOGIES 58
5.3.2.1 Virtual reality 58
5.3.2.2 Digital therapeutics 58
5.3.3 ADJACENT TECHNOLOGIES 58
5.3.3.1 Robotics 58
5.4 INDUSTRY TRENDS 58
5.4.1 ELECTROTHERAPY DEVICES 58
5.4.2 RECHARGEABLE SPINAL CORD STIMULATORS 59
5.5 SUPPLY CHAIN ANALYSIS 59
5.6 TRADE ANALYSIS 61
5.7 PORTER’S FIVE FORCES ANALYSIS 62
5.7.1 THREAT FROM NEW ENTRANTS 63
5.7.2 THREAT FROM SUBSTITUTES 64
5.7.3 BARGAINING POWER OF SUPPLIERS 64
5.7.4 BARGAINING POWER OF BUYERS 64
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 65
 
5.8 REGULATORY LANDSCAPE 65
5.8.1 NORTH AMERICA 66
5.8.1.1 US 66
5.8.1.2 Canada 67
5.8.2 EUROPE 68
5.8.3 ASIA PACIFIC 71
5.8.3.1 Japan 71
5.8.3.2 China 71
5.8.3.3 India 72
5.8.4 LATIN AMERICA 73
5.8.4.1 Brazil 73
5.8.4.2 Mexico 75
5.8.5 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 77
5.9 PATENT ANALYSIS 80
5.10 PRICING ANALYSIS 82
5.11 KEY CONFERENCES AND EVENTS, 2024–2025 83
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 84
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 84
5.12.2 BUYING CRITERIA 85
5.13 ECOSYSTEM ANALYSIS 86
5.14 CASE STUDY ANALYSIS 88
5.15 REIMBURSEMENT ANALYSIS 89
5.16 UNMET NEEDS IN PAIN MANAGEMENT DEVICES MARKET 90
5.17 VALUE CHAIN ANALYSIS 91
5.18 END USER EXPECTATIONS IN PAIN MANAGEMENT DEVICES MARKET 92
5.19 IMPACT OF AI/GEN AI IN PAIN MANAGEMENT DEVICES MARKET 93
5.20 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93
5.21 INVESTMENT AND FUNDING SCENARIO 94
6 PAIN MANAGEMENT DEVICES MARKET, BY TYPE 95
6.1 INTRODUCTION 96
6.2 NEUROSTIMULATION DEVICES 96
6.2.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS 99
6.2.1.1 Surge in demand for non-invasive therapy to drive market 99
6.2.2 SPINAL CORD STIMULATORS 101
6.2.2.1 Extensive use of SCS for pain treatment to drive market 101
6.2.3 OTHERS 103
6.3 INFUSION PUMPS 105
6.3.1 INTRATHECAL INFUSION PUMPS 107
6.3.1.1 Increasing incidences of chronic pain to drive market 107
 
6.3.2 EXTERNAL INFUSION PUMPS 109
6.3.2.1 Availability of reimbursement to drive market 109
6.4 ABLATION DEVICES 111
6.4.1 RADIOFREQUENCY ABLATION DEVICES 113
6.4.1.1 Low cost of RF ablation procedures to drive market 113
6.4.2 CRYOABLATION ABLATION DEVICES 115
6.4.2.1 Successful clinical trials to drive market 115
6.4.3 ULTRASOUND ABLATION DEVICES 116
6.4.3.1 Efficacy in targeted pain management to drive market 116
6.4.4 OTHERS 118
7 PAIN MANAGEMENT DEVICES MARKET, BY APPLICATION 119
7.1 INTRODUCTION 120
7.2 NEUROPATHIC PAIN 120
7.2.1 HIGH EFFICACY OF PAIN MANAGEMENT DEVICES IN NEUROPATHIC
PAIN TREATMENT TO DRIVE MARKET 120
7.3 MUSCULOSKELETAL PAIN 122
7.3.1 SURGE IN AGING POPULATION TO DRIVE MARKET 122
7.4 CANCER PAIN 124
7.4.1 PREVALENCE OF CANCER TO DRIVE MARKET 124
7.5 FACIAL PAIN & MIGRAINE 126
7.5.1 INTRODUCTION OF NOVEL PAIN MANAGEMENT DEVICES TO DRIVE MARKET 126
7.6 OTHER APPLICATIONS 127
8 PAIN MANAGEMENT DEVICES MARKET, BY MODE OF PURCHASE 129
8.1 INTRODUCTION 130
8.2 PRESCRIPTION-BASED 130
8.2.1 INCREASING INCIDENCES OF MEDICAL DISORDERS TO DRIVE MARKET 130
8.3 OVER-THE-COUNTER 132
8.3.1 ACCESSIBILITY OF OTC PAIN MANAGEMENT DEVICES TO DRIVE MARKET 132
9 PAIN MANAGEMENT DEVICES MARKET, BY END USER 134
9.1 INTRODUCTION 135
9.2 HOSPITALS & CLINICS 135
9.3 PHYSIOTHERAPY CENTERS 137
9.3.1 RISE OF SPORTS INJURIES AND MUSCULOSKELETAL DISORDERS
TO DRIVE MARKET 137
9.4 HOME CARE SETTINGS 139
9.4.1 HIGH COST OF HOSPITALIZATION TO DRIVE MARKET 139
9.5 OTHER END USERS 141
 
10 PAIN MANAGEMENT DEVICES MARKET, BY REGION 142
10.1 INTRODUCTION 143
10.2 NORTH AMERICA 143
10.2.1 MACROECONOMIC OUTLOOK 147
10.2.2 US 148
10.2.2.1 Favorable reimbursement policies to drive market 148
10.2.3 CANADA 151
10.2.3.1 Increasing incidences of chronic pain to drive market 151
10.3 EUROPE 154
10.3.1 MACROECONOMIC OUTLOOK 157
10.3.2 GERMANY 158
10.3.2.1 Robust healthcare infrastructure to drive market 158
10.3.3 FRANCE 161
10.3.3.1 Government initiatives for lowering healthcare costs to drive market 161
10.3.4 UK 164
10.3.4.1 Shift toward home care settings to drive market 164
10.3.5 ITALY 167
10.3.5.1 Growing healthcare investments to drive market 167
10.3.6 SPAIN 169
10.3.6.1 Surge in new cancer cases to drive market 169
10.3.7 REST OF EUROPE 172
10.4 ASIA PACIFIC 175
10.4.1 MACROECONOMIC OUTLOOK 179
10.4.2 JAPAN 181
10.4.2.1 Large geriatric population to drive market 181
10.4.3 CHINA 183
10.4.3.1 Growing investments in healthcare infrastructure development to drive market 183
10.4.4 INDIA 186
10.4.4.1 High prevalence of lifestyle diseases to drive market 186
10.4.5 AUSTRALIA 189
10.4.5.1 Initiatives promoting development of novel pain management devices to drive market 189
10.4.6 SOUTH KOREA 192
10.4.6.1 Growing demand for effective treatment options to drive market 192
10.4.7 REST OF ASIA PACIFIC 194
10.5 LATIN AMERICA 197
10.5.1 MACROECONOMIC OUTLOOK 200
10.5.2 BRAZIL 201
10.5.2.1 Private and government sector awareness programs to drive market 201
10.5.3 MEXICO 204
10.5.3.1 Domestic health coverage schemes to drive market 204
10.5.4 REST OF LATIN AMERICA 206
10.6 MIDDLE EAST & AFRICA 209
10.6.1 MACROECONOMIC OUTLOOK 212
10.6.2 GCC COUNTRIES 213
10.6.2.1 High healthcare spending capacity to drive market 213
10.6.3 REST OF MIDDLE EAST & AFRICA 216
11 COMPETITIVE LANDSCAPE 219
11.1 INTRODUCTION 219
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024 219
11.3 REVENUE ANALYSIS, 2021–2023 220
11.4 MARKET SHARE ANALYSIS, 2023 221
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 222
11.5.1 STARS 223
11.5.2 EMERGING LEADERS 223
11.5.3 PERVASIVE PLAYERS 223
11.5.4 PARTICIPANTS 223
11.5.5 COMPANY FOOTPRINT 224
11.5.5.1 Company footprint 225
11.5.5.2 Type footprint 226
11.5.5.3 Region footprint 227
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 228
11.6.1 PROGRESSIVE COMPANIES 228
11.6.2 RESPONSIVE COMPANIES 228
11.6.3 DYNAMIC COMPANIES 228
11.6.4 STARTING BLOCKS 228
11.6.5 COMPETITIVE BENCHMARKING 230
11.7 BRAND/PRODUCT COMPARISON 231
11.8 R&D ASSESSMENT 232
11.9 COMPANY VALUATION AND FINANCIAL METRICS 232
11.10 COMPETITIVE SCENARIO 233
11.10.1 PRODUCT APPROVALS/LAUNCHES 233
11.10.2 DEALS 234
11.10.3 EXPANSIONS 235
11.10.4 OTHERS 235
12 COMPANY PROFILES 236
12.1 KEY PLAYERS 236
12.1.1 MEDTRONIC 236
12.1.1.1 Business overview 236
12.1.1.2 Products offered 237
12.1.1.3 Recent developments 238
12.1.1.3.1 Product approvals/launches 238
12.1.1.4 MnM view 239
12.1.1.4.1 Key strengths 239
12.1.1.4.2 Strategic choices 239
12.1.1.4.3 Weaknesses and competitive threats 239
12.1.2 BOSTON SCIENTIFIC CORPORATION 240
12.1.2.1 Business overview 240
12.1.2.2 Products offered 241
12.1.2.3 Recent developments 242
12.1.2.3.1 Deals 242
12.1.2.4 MnM view 242
12.1.2.4.1 Key strengths 242
12.1.2.4.2 Strategic choices 242
12.1.2.4.3 Weaknesses and competitive threats 242
12.1.3 ABBOTT LABORATORIES 243
12.1.3.1 Business overview 243
12.1.3.2 Product offered 244
12.1.3.3 Recent developments 245
12.1.3.3.1 Product approvals/launches 245
12.1.3.4 MnM view 245
12.1.3.4.1 Key strengths 245
12.1.3.4.2 Strategic choices 245
12.1.3.4.3 Weaknesses and competitive threats 246
12.1.4 NEVRO CORP. 247
12.1.4.1 Business overview 247
12.1.4.2 Products offered 248
12.1.4.3 Recent developments 248
12.1.4.3.1 Product approvals/launches 248
12.1.4.3.2 Deals 248
12.1.4.4 MnM view 249
12.1.4.4.1 Key strengths 249
12.1.4.4.2 Strategic choices 249
12.1.4.4.3 Weaknesses and competitive threats 249
12.1.5 BECTON, DICKINSON AND COMPANY 250
12.1.5.1 Business overview 250
12.1.5.2 Products offered 251
12.1.5.3 Recent developments 252
12.1.5.3.1 Others 252
12.1.5.4 MnM view 252
12.1.5.4.1 Right to win 252
12.1.5.4.2 Strategic choices 252
12.1.5.4.3 Weaknesses and competitive threats 252
12.1.6 STRYKER 253
12.1.6.1 Business overview 253
12.1.6.2 Products offered 254
12.1.6.3 Recent developments 255
12.1.6.3.1 Expansions 255
12.1.7 B. BRAUN SE 256
12.1.7.1 Business overview 256
12.1.7.2 Products offered 257
12.1.7.3 Recent developments 259
12.1.7.3.1 Deals 259
12.1.7.3.2 Others 259
12.1.8 BAXTER 260
12.1.8.1 Business overview 260
12.1.8.2 Products offered 262
12.1.9 OMRON CORPORATION 263
12.1.9.1 Business overview 263
12.1.9.2 Products offered 264
12.1.10 AVANOS MEDICAL, INC. 265
12.1.10.1 Business overview 265
12.1.10.2 Products offered 266
12.1.10.2.1 Deals 266
12.1.11 TELEFLEX INCORPORATED 267
12.1.11.1 Business overview 267
12.1.11.2 Products offered 268
12.1.12 ICU MEDICAL, INC. 269
12.1.12.1 Business overview 269
12.1.12.2 Products offered 270
12.1.12.3 Recent developments 271
12.1.12.3.1 Deals 271
12.1.13 NIPRO 272
12.1.13.1 Business overview 272
12.1.13.2 Products offered 274
12.1.13.3 Recent developments 274
12.1.13.3.1 Expansions 274
12.1.14 MOOG INC. 275
12.1.14.1 Business overview 275
12.1.14.2 Products offered 277
12.1.15 ATRICURE, INC. 278
12.1.15.1 Business overview 278
12.1.15.2 Products offered 279
12.1.15.3 Recent developments 279
12.1.15.3.1 Product approvals/launches 279
12.1.16 MICREL MEDICAL DEVICES SA 280
12.1.16.1 Business overview 280
12.1.16.2 Products offered 281
12.1.17 ZYNEX, INC. 282
12.1.17.1 Business overview 282
12.1.17.2 Products offered 283
12.1.18 ENOVIS CORPORATION 284
12.1.18.1 Business overview 284
12.1.18.2 Products offered 285
12.2 OTHER PLAYERS 286
12.2.1 EPIC MEDICAL 286
12.2.2 SOTERIX MEDICAL INC. 286
12.2.3 GIMER MEDICAL 287
12.2.4 NEURONANO AB 287
12.2.5 ICECURE MEDICAL 288
12.2.6 BIOWAVE 288
12.2.7 THERANICA BIO-ELECTRONICS LTD. 289
13 APPENDIX 290
13.1 DISCUSSION GUIDE 290
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 294
13.3 CUSTOMIZATION OPTIONS 296
13.4 RELATED REPORTS 296
13.5 AUTHOR DETAILS 297